New Directions For US Biotech: E&Y Report

5 December 1997

Despite ups and down, the US biotechnology sector has gained momentumover the last year, according to Kenneth Lee, co-chairman of the Ernst & Young International Life Sciences Practice. Speaking at a recent briefing in London, Mr Lee said that findings from research, to be published early-1998 in a report entitled US Biotech 98 - New Directions, will confirm that biotechnology continues to grow rapidly, and it is showing new directions.

Biotechnology company sales, the report will reveal, grew 20% in the year ended June 1997, to a value of $13 billion. For the same period, net losses fell 9% to $4.1 billion, and the number of people employed in the sector rose 19% to 140,000.

Highest-Ever Market Capitalization Another finding of the report is that as at September 30, the total market capitalization of the US biotechnology industry was $118 billion, its highest point ever. Strategic alliance activity maintained a healthy pace.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight